Table 1

Summary of patients investigated for CD4+CD28null T cells in synovial membrane biopsies
Patient
 Gender, age (years)
 Disease duration (years)
 Treatmenta
 Erosive disease
 CD3+ in synovial membraneb
 CD4+CD28null T cells












Peripheral blood (%)
 Synovial fluid (%)
 n/T-cell infiltratec
 n/mm2 T-cell infiltratec
>5% CD4+CD28null T cells in peripheral blood
     1
 Female, 69
 1
 P, M
 -
 ++
 18
 6
 3
 35
     2
 Female, 45
 15
 N, L
 +
 +
 9.8
 10.4
 2.5
 54
     3
 Female, 67
 2.75
 N
 +
 ++
 7.6
 6.5
 5
 47
     4
 Female, 51
 33
 N, P
 +
 +++
 13
 1.5
 4.7
 48
     5
 Male, 74
 26
 N, P, E
 +
 ++
 8.6
 2.7
 0.8
 5
     6
 Male, 38
 22
 N, M, E
 +
 ++
 8
 0.8
 2
 39
<1% CD4+CD28null T cells in peripheral blood
     7
 Male, 45
 13
 N
 +
 +
 0
 0.4
 1.3
 53
     8
 Male, 25
 0.6
 N, P, M
 -
 ++
 0
 0.2
 3
 51
     9
 Female, 60
 Several years
 N, D
 -
 ++
 0
 0.1
 0
 0
     10
 Male, 41
 1
 P
 +
 +++
 0.4
 0.8
 4.5
 67
     11
 Female, 66
 10
 M
 +
 ++
 0.4
 0.6
 0
 0

aP, prednisolone; M, methotrexate; N, nonsteroidal anti-inflammatory drug; L, leflunomid; E, etanercept; D, depomedrol. bRelative size of infiltrating CD3+ cells in the synovial membrane specimen: +, <25% T cells in the tissue area; ++, approximately 50% T cells in the tissue area; +++, >75% T cells in the tissue area. cAverage numbers of CD4+CD28null T cells in one to five analysed infiltrates.

Fasth et al. Arthritis Research & Therapy 2007 9:R87   doi:10.1186/ar2286